Trial profile

Fox K et al. Lancet 2008;372:807-16

Baseline characteristics

Fox K et al. Lancet 2008;372:807-16

Baseline characteristics of the subgroup with heart rate of 70 bpm or greater

Fox K et al. Lancet 2008;372:807-16

Mean heart rate during the study (A) in the total study population and (B) in the subgroup

with heart rate of 70 bpm or greater

Fox K et al. Lancet 2008;372:807-16

Incidence of serious adverse events during the study by system organ class

Fox K et al. Lancet 2008;372:807-16

Primary and secondary endpoints

Fox K et al. Lancet 2008;372:807-16

Kaplan–Meier time-to-event plot, by treatment group for composite primary endpoint in the total study population

Fox K et al. Lancet 2008;372:807-16

Effect of treatment on composite primary endpoint in prespecified subgroups

Fox K et al. Lancet 2008;372:807-16

Kaplan–Meier time-to-event plot, by treatment group in the prespecified subgroup with heart rate of

70 bpm or greater for composite primary endpoint

Fox K et al. Lancet 2008;372:807-16

Kaplan–Meier time-to-event plots, by

treatment group in the prespecifi ed subgroup

with heart rateof 70 bpm or greater,

for the secondary endpoints of (A)

admission to hospital for new-onset or

worsening heart failure and (B) cardiovascular

death or admission to hospital for new-onset or worsening

heart failure

Fox K et al. Lancet 2008;372:807-16

Kaplan–Meier time-to-event plots, by

treatment group in the prespecifi ed subgroup

with heart rateof 70 bpm or greater

for the secondary endpoints of (A)

admission to hospital for acute myocardial

infarction endpoint and (B) admission to hospital for acute

myocardial infarction or unstable angina

Fox K et al. Lancet 2008;372:807-16

Kaplan–Meier time-to-event plot, by treatment group in the prespecified subgroup with heart rate of 70 bpm or greater

for secondary endpoint of coronary revascularisation

Fox K et al. Lancet 2008;372:807-16